Bone Biologics Corp — Director's Dealing 2025

Jun 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2025-06-04

Reporting Person: Meikle Phillip Terry II (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-04	Non-Employee Stock Option	$0.88	A	62894	Acquired	2035-06-04	Common Stock (62894)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Employee Stock Option	$1.88	2034-10-16	Common Stock (28185)	28185	Direct
Non-Employee Stock Option	$1.88	2034-10-16	Common Stock (9)	9	Direct

Footnotes

F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

F2: This option was granted on 10/16/2024 and vests in equal installments on each of 12/17/2024, 3/19/2025, 6/19/2025 and 9/17/2025.

F3: This option is fully exercisable as of the date of this report.